Claris Ventures

Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases. In recent years Kither has focused its first line of activities on the development of a small peptide (KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development. Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.

Resalis Therapeutics is a biopharmaceutical company focused on transforming the treatment of metabolic diseases, particularly obesity and fatty liver disease, by developing innovative therapies that target key regulatory pathways. The company's leading program, RES-010, utilizes its expertise in non-coding RNA drug modalities and lipid metabolism to create a treatment that aims for long-term weight loss and reduced liver fat accumulation. With a strong foundation of preclinical evidence, Resalis is progressing RES-010 into clinical trials, offering potential disease-modifying effects and a safe, convenient therapeutic option for patients suffering from various metabolic disorders.

Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases. In recent years Kither has focused its first line of activities on the development of a small peptide (KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development. Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.